Product search
Filter
Search results
HEMOCLOT Factor VIIa Reagent
Assay proposed for the measurement of factor VIIa activity citrated plasma or purified medium.
BIOPHEN FVIIa Control Set
BIOPHEN FVIIa Control Set is a set of controls intended for the quality control of activated factor VII (FVIIa) activity measurements, the BIOPHEN FVIIs colorimetric assay with the kit BIOPHEN Factor VIIa (ref. 221312) and the clotting assay with the kit HEMOCLOT Factor VIIa assay (ref. CK092K).
CoaChrom® Prothrombin -> SEE NEW REF. 400001
Assay proposed for the measurement of prothrombin (Factor II) in research applications.
BIOPHEN Antithrombin LRT (anti-(h)-Xa, Liquid Reagent Technology)
Diagnosis of congenital or acquired antithrombin deficiencies.
BIOPHEN Antithrombin LRT (anti-(h)-Xa, Liquid Reagent Technology)
Diagnosis of congenital or acquired antithrombin deficiencies.
Ristocetin
The ristocetin reagent is proposed for platelet aggregation tests, as an aid for the detection of von Willebrand disease, von Willebrand factor (vWF) determination, and identification of Bernard-Soulier syndrome.
Collagen
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome, storage pool disease) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDs and GPIIb/IIIa inhibitors.
Epinephrine
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDsand GPIIb/IIIa inhibitors.
Arachidonic Acid
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDsand GPIIb/IIIa inhibitors.
ADP Assay for Platelet Aggregation
Investigation of congenital (e.g. Glanzmann’s thrombasthenia, Bernard-Soulier, gray platelet syndrome) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma, hepatic or renal failure). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDs and GPIIb/IIIa inhibitors.